Vitamin D and multiple sclerosis;Vitamina D y esclerosis múltiple

Revista de Neurologia

Volumn 56, Issue 4, 2013, Pages 243-251

  Pozuelo Moyano, Beatriz ^a,b   Benito León, Julián ^a,b,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Multiple sclerosis; Review; Vitamin D

Indexed keywords

VITAMIN D;

DISEASE ASSOCIATION; MULTIPLE SCLEROSIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; BLOOD; HUMAN; PHYSIOLOGY;

HUMANS; MULTIPLE SCLEROSIS; VITAMIN D;

EID: 84874215598     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5604.2012622     Document Type: Review

References (79)

1. Benito-León J, Bermejo-Pareja F. ¿Está cambiando la epidemiología de la esclerosis múltiple? Rev Neurol 2010; 51: 385-6.
2. Benito-León J, Martín E, Vela L, Villar ME, Felgueroso B, Marrero C, et al. Multiple sclerosis in Móstoles, central Spain. Acta Neurol Scand 1998; 98: 238-42.
3. Rivera-Navarro J, Benito-León J, Morales-González JM. Hacia la búsqueda de dimensiones más específicas en la medición de la calidad de vida en la esclerosis múltiple. Rev Neurol 2001; 32: 705-13.
4. Benito-León J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002; 9: 497-502.
5. Benito-León J, Martínez-Martín P. Calidad de vida relacionada con la salud en la esclerosis múltiple. Neurologia 2003; 18: 210-7.
6. Benito-León J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on healthrelated quality of life. Disabil Rehabil 2003; 25: 1291-303.
7. Rivera-Navarro J, Morales-González JM, Benito-León J, Madrid Demyelinating Diseases Group. Informal caregiving in multiple sclerosis patients: data from the Madrid Demyelinating Disease Group study. Disabil Rehabil 2003; 25: 1057-64.
8. Morales-Gonzales JM, Benito-León J, Rivera-Navarro J, Mitchell AJ, Group GS. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. Mult Scler 2004; 10: 47-54.
9. Mitchell AJ, Benito-León J, González JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4: 556-66.
10. Rivera-Navarro J, Morales-González JM, Benito-León J, Mitchell AJ. Dimensión social y familiar: experiencias de cuidadores y personas con esclerosis múltiple. El estudio GEDMA. Rev Neurol 2008; 47: 281-5.
11. Rivera-Navarro J, Benito-León J, Oreja-Guevara C, Pardo J, Dib WB, Orts E, et al. Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler 2009; 15: 1347-55.
12. Rivera-Navarro J, Benito-León J. Dimensión social de la calidad de vida en la esclerosis múltiple. Rev Neurol 2011; 52: 127.
13. Benito-León J, Rivera-Navarro J, Guerrero AL, De Las Heras V, Balseiro J, Rodríguez E, et al. The CAREQOL-MS was a useful instrument to measure caregiver quality of life in multiple sclerosis. J Clin Epidemiol 2011; 64: 675-86.
14. Benito-León J, Mitchell AJ, Rivera-Navarro J, Morales-González JM. Impaired health-related quality of life predicts progression of disability in multiple sclerosis. Eur J Neurol 2013; 20: 79-86.
15. Fernández O, Álvarez-Cermeño JC, Arroyo-González R, Brieva LL, Calles-Hernández MC, Casanova-Estruch B, et al, Grupo Post-ECTRIMS. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I). Rev Neurol 2012; 54: 677-91.
16. Brahic M. Multiple sclerosis and viruses. Ann Neurol 2010; 68: 6-8.
17. Jafari N, Hintzen RQ. The association between cigarette smoking and multiple sclerosis. J Neurol Sci 2011; 311: 78-85.
18. Benito-León J, Pisa D, Alonso R, Calleja P, Díaz-Sánchez M, Carrasco L. Association between multiple sclerosis and Candida species: evidence from a case-control study. Eur J Clin Microbiol Infect Dis 2010; 29: 1139-45.
19. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand 1960; 35: 132-47.
20. Carlyle IP. Multiple sclerosis: a geographical hypothesis. Med Hypotheses 1997; 49: 477-86.
21. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med 1997; 216: 21-7.
22. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009; 256: 1468-79.
23. Stroud ML, Stilgoe S, Stott VE, Alhabian O, Salman K. Vitamin D-a review. Aust Fam Physician 2008; 37: 1002-5.
24. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
25. Holick MF. Vitamin D, sunlight and cancer connection. Anticancer Agents Med Chem 2012; Oct 12 [Epub ahead of print].
26. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010; 88: 441-50.
27. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem 2003; 88: 296-307.
28. Giulietti A, Van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007; 77: 47-57.
29. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest 1987; 79: 1659-64.
30. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al. Vitamin D and musculoskeletal health, cardio-vascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010; 9: 709-15.
31. Davis CD. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr 2008; 88: S565-9.
32. Smolders J. Vitamin D and multiple sclerosis: correlation, causality, and controversy. Autoimmune Dis 2011; 2011: 629538.
33. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005; 11: 266-71.
34. Simpson S, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203.
35. Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011; 10: 436-45.
36. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
37. Van der Mei I, Ponsonby AL, Dwyer T, Blizzard L, Taylor B, Kilpatrick T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007; 254: 581-90.
38. Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72: 234-40.
39. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-91.
40. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520-32.
41. Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 2010; 340: c1640.
42. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005; 330: 120.
43. Abad EP, Alarcón T, Castro E, Díaz F, Santibáñez R. Epidemiological evidence of multiple sclerosis in Ecuador. Mult Scler 2008; 14 (Suppl 1): S55-6.
44. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129-35.
45. Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol 2007; 103: 620-5.
46. Van der Mei IA, Blizzard L, Ponsonby AL, Dwyer T. Validity and reliability of adult recall of past sun exposure in a case-control study of multiple sclerosis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1538-44.
47. Decard BF, Von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 1170-3.
48. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010; 6: 156-66.
49. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-8.
50. Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, Mowry EM, et al. Vitamin D in African Americans with multiple sclerosis. Neurology 2011; 76: 1824-30.
51. Huang J, Xie ZF. Polymorphisms in the vitamin D receptor gene and multiple sclerosis risk: a meta-analysis of casecontrol studies. J Neurol Sci 2012; 313: 79-85.
52. Cox MB, Ban M, Bowden NA, Baker A, Scott RJ, Lechner-Scott J. Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis. Mult Scler 2012; 18: 16-22.
53. Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, Ascherio A. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol 2011; 258: 1676-82.
54. Ramagopalan SV, Dyment DA, Cader MZ, Morrison KM, Disanto G, Morahan JM, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011; 70: 881-6.
55. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009; 132: 1146-60.
56. Royal W 3rd, Mia Y, Li H, Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol 2009; 213: 135-41.
57. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009; 5: e1000369.
58. Smolders J, Peelen E, Thewissen M, Cohen-Tervaert JW, Menheere P, Hupperts R, et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010; 5: e15235.
59. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006; 92: 60-4.
60. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 dihydroxy-vitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 2006; 83: 1299-309.
61. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J Neuroimmunol 1995; 61: 151-60.
62. Cantorna MT. Vitamin D and multiple sclerosis: an update. Nutr Rev 2008; 66 (Suppl 2): S135-8.
63. Nashold FE, Miller DJ, Hayes CE. 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2000; 103: 171-9.
64. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005; 175: 4119-26.
65. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 2007; 85: 2480-90.
66. Chaudhuri A. Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses 2005; 64: 608-18.
67. Holmoy T, Lossius A, Gundersen TE, Moen SM, Castellazzi M, Fainardi E, et al. Intrathecal levels of vitamin D and IgG in multiple sclerosis. Acta Neurol Scand 2012; 125: e28-31.
68. Jagannath VA, Fedorowicz Z, Asokan GV, Robak EW, Whamond L. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev 2010; 12: CD008422.
69. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74: 1852-9.
70. Pozuelo-Moyano B, Benito-León J, Mitchell AJ, Hernández-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology 2012; 40: 147-53.
71. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 2011; 40: 627-39.
72. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77: 1611-8.
73. Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012; 18: 1144-51.
74. Soilu-Hänninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 565-71.
75. Aivo J, Lindsrom BM, Soilu-Hanninen M. A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012; 2012: 802796.
76. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012; 2012: 452541.
77. Ho SL, Alappat L, Awad AB. Vitamin D and multiple sclerosis. Crit Rev Food Sci Nutr 2012; 52: 980-7.
78. Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, et al. Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311: 44-9.
79. Dorr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012; 13: 15.